Other3

Aspen Neuroscience, Inc.

Total Value

$NaN

Filing Date

Oct 29, 2026

1 transactions

Trade Summary

On Oct 29, 2026, Spaventa Andrew, Insider, reported $NaN of Aspen Neuroscience, Inc. (ASPE) across 1 transactions. The filing covers company securities and reflects balanced net activity of $NaN. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.

Insider Information

Name: Spaventa Andrew
Role: Insider
Location: SAN DIEGO, CA

Filing Details

Filing Date: Oct 29, 2026
Transaction Date: Oct 29, 2026
Accession Number: 0001193125-26-439144
Form Type: 3

Want live alerts when Spaventa Andrew trades again?

Download Insider Trades to track ASPE, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.

iOS App Android App

Footnotes

(F1)Shares of Common Stock held by The Andrew K. Spaventa Living Trust Dated April 9, 2014.
(F2)Pursuant to the Issuer's Amended and Restated Certificate of Incorporation, as amended, each share of Series Seed Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") may be converted, at the option of the holder, at any time. In connection with the completion of the Issuer's initial public offering of its Common Stock, each share of Preferred Stock will automatically convert on a 1-for-9.8821 basis into shares of Common Stock, for no additional consideration. Share numbers give effect to such conversion. The securities have no expiration date.
(F3)Securities held by Axon Holdings, LLC Series XIII - Aspen Seed, of which Mr. Spaventa is a managing partner.
(F4)Securities held by Axon Holdings, LLC Series XXI - Aspen C, of which Mr. Spaventa is a managing partner.
(F5)The option was granted on June 16, 2022. The option is fully vested and exercisable.
(F6)The option was granted on November 26, 2025. The shares subject to the option were previously eligible to vest in 48 equal monthly installments beginning on December 20, 2025. In September 2026, the vesting schedule was amended such that the unvested shares subject to the option as of September 25, 2026, shall vest in equal monthly installments through November 20, 2031, subject to the Reporting Person's continuous service through each vesting date.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Spaventa Andrew

(Last)

(First)

(Middle)

10835 ROAD TO THE CURE, SUITE 100

(Street)

SAN DIEGO

92121

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
10/29/2026

3. Issuer Name and Ticker or Trading Symbol
Aspen Neuroscience, Inc. [ ASPE ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	7,747	D
Common Stock	49,914	I	See Footnote 1.⁽¹⁾

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Series Seed Convertible Preferred Stock	⁽²⁾	⁽²⁾	Common Stock	70,194	⁽²⁾	I	See Footnote 3.⁽³⁾
Series C Convertible Preferred Stock	⁽²⁾	⁽²⁾	Common Stock	180,221	⁽²⁾	I	See Footnote 4.⁽⁴⁾
Stock Option (Right to Buy)	⁽⁵⁾	06/15/2032	Common Stock	29,345	$7.71	D
Stock Option (Right to Buy)	⁽⁶⁾	11/25/2035	Common Stock	19,226	$5.74	D

Explanation of Responses:

1. Shares of Common Stock held by The Andrew K. Spaventa Living Trust Dated April 9, 2014.

2. Pursuant to the Issuer's Amended and Restated Certificate of Incorporation, as amended, each share of Series Seed Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") may be converted, at the option of the holder, at any time. In connection with the completion of the Issuer's initial public offering of its Common Stock, each share of Preferred Stock will automatically convert on a 1-for-9.8821 basis into shares of Common Stock, for no additional consideration. Share numbers give effect to such conversion. The securities have no expiration date.

3. Securities held by Axon Holdings, LLC Series XIII - Aspen Seed, of which Mr. Spaventa is a managing partner.

4. Securities held by Axon Holdings, LLC Series XXI - Aspen C, of which Mr. Spaventa is a managing partner.

5. The option was granted on June 16, 2022. The option is fully vested and exercisable.

6. The option was granted on November 26, 2025. The shares subject to the option were previously eligible to vest in 48 equal monthly installments beginning on December 20, 2025. In September 2026, the vesting schedule was amended such that the unvested shares subject to the option as of September 25, 2026, shall vest in equal monthly installments through November 20, 2031, subject to the Reporting Person's continuous service through each vesting date.

Remarks:

Exhibit 24 - Power of Attorney

	By: /s/ Jeffrey L. Boerneke, as Attorney-in-Fact	10/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Form 3 as rendered by the SEC from accession 0001193125-26-439144.

Aspen Neuroscience, Inc.

Trade Summary

Company Information

Insider Information

Filing Details

Want live alerts when Spaventa Andrew trades again?

Footnotes

SEC Form 3

SEC Filing

SEC Form 3